Log in to the Sina Finance APP and search for [Xinphi] to see more evaluation grades

Transferred from: Prospective Industry Research Institute

Major listed companies in the animal vaccine industry: China Animal Husbandry Co., Ltd. (600195); Biological shares (600201); Rip Biotech (300119); Pleco (603566); Pre-family biology (688526); Yongshun Biotech (839729); Shenlian Biotechnology (688098); Haili Biotech (603718) and so on

The core data of this paper: the number of animal vaccine manufacturers in China; the market size of China's animal vaccine industry; the scale of China's animal vaccine import and export; China's animal vaccine competition landscape

Industry Overview

1. Definitions

Animal vaccine, also known as animal vaccine, is made of pathogenic microorganisms with good immunogenicity after reproduction and treatment, after inoculating the animal body, stimulate the body to produce specific antibodies, when the antibody titer in the body reaches a certain value, it can resist the invasion and infection of this pathogenic microorganism, and play a role in preventing this disease, and the main role of animal vaccines is to prevent infectious diseases.

Animal vaccines can be divided into two categories: bacterial vaccines and viral vaccines according to biological materials. According to the use of animals, it can be divided into poultry vaccines, pig vaccines, cattle and sheep vaccines, pet vaccines and aquatic vaccines. According to the technology, it can be divided into conventional vaccines and new vaccines.

2. Analysis of the industrial chain: the upstream and downstream are closely related

The upstream of the animal vaccine industry is mainly used in the production of vaccines, such as fillers, culture media, trypsin and other raw materials, as well as production equipment and packaging materials; The midstream is an animal vaccine R&D and production enterprise; The downstream is the application market of cold chain transportation, animal husbandry, pet industry and so on.

The upstream raw material suppliers mainly include Yuanpei Biotechnology, Zhonghai Biotechnology and other enterprises, and the representative enterprises of vaccine production equipment and packaging materials include Zhengchuan Co., Ltd., Shandong Pharmaceutical Glass, Chutian Technology, etc.; Midstream animal vaccine manufacturers include China Animal Husbandry Co., Ltd., Ruipu Biotechnology, Pleco, etc.; Downstream cold chain logistics companies mainly include SF Express, Zhongchuang Logistics, etc., and representative vaccine application companies include Muyuan Co., Ltd., Wen's Co., Ltd., New Hope, etc.

Industry development history: enter the stage of standardized development

The development of China's animal vaccine industry has mainly entered four stages of development, including the initial stage, the extensive development stage, the rapid development stage, and the standardized development stage. On June 1, 2020, the new version of the veterinary drug GMP began to be implemented, and the regulatory policies of China's animal vaccine industry were gradually improved, and the industry entered a stage of standardized development.

Industry policy background: Improve the supervision of the vaccine industry

Since 2020, the state has gradually improved the supervision of the vaccine industry, and successively issued policies such as the Notice on the Implementation of Commissioned Production of Veterinary Drugs during the New Version of Veterinary Drug GMP Transition Period and the Notice on Printing and Distributing Three Plans for Veterinary Drug Quality Supervision, Sampling and Risk Monitoring in 2024 to improve the quality of animal vaccine products. The summary and interpretation of the key policies of China's animal vaccine industry from 2020 to 2024 are as follows:

The current situation of supply and demand in the industry

1. The total number of animal vaccine registrations in China: the number of new registrations will reach 28 in 2023

From 2019 to 2023, the number of animal vaccine registrations in China fluctuated, with the largest number of new registrations in 2021 reaching 32, and the number of new registrations in 2023 being 28, an increase of 10 from 2022.

From 2019 to 2023, the total number of newly registered products of China's pig-related vaccines will reach 52, of which the largest number of new registrations will be in 2021, reaching 15. In 2023, the number of pig-related vaccines registered in China will reach 13, an increase of 6 from 2022.

In terms of poultry vaccines, the total number of newly registered products from 2019 to 2023 will reach 47, of which 12 will be newly registered in 2019 and 2021. In 2023, the number of poultry vaccine registrations in China will reach 10, an increase of 4 from 2022.

2. China's import and export scale of animal vaccines: The import and export scale will decline in 2023

From the perspective of imports, the import volume of animal vaccines in China from 2018 to 2023 is in a state of fluctuation. In 2023, China's animal vaccine imports will be 1,223 tons, a year-on-year decrease of 12.19%. From January to May 2024, China's animal vaccine exports were 561 tons.

From the perspective of exports, the export volume of animal vaccines in China from 2018 to 2022 showed an upward trend. In 2022, China's overall export volume of animal vaccines will be 831.6 tons, a year-on-year increase of 36.80%. The export volume in 2023 will be 749.92 tons, a year-on-year decrease of 9.82%. From January to May 2024, China's animal vaccine exports were 476.57 tons.

3. Market size of China's animal vaccine industry: The market size will be about 2.7 billion US dollars in 2023

Frost & Sullivan data shows that since 2018, the scale of China's animal vaccine industry has shown a fluctuating upward trend. In 2022, the size of China's animal vaccine industry reached US$2.5 billion, basically the same as in 2021. According to preliminary statistics, the market size of China's animal vaccine industry in 2023 will be about 2.7 billion US dollars.

The competitive landscape of the industry

1. Analysis of enterprise competition pattern

According to the survey data of Xinzhupai, in 2023, the top 3 companies in the revenue scale of the animal vaccine business of China's domestic animal vaccine manufacturers are Yibang Biological, China Animal Husbandry Co., Ltd. and Ruipu Biotech, and the revenue scale of the animal vaccine business is more than 1 billion yuan.

2. Analysis of regional competition pattern

From the perspective of regional distribution, China's animal vaccine listed companies are mainly distributed in Shanghai, Guangdong, Inner Mongolia, Beijing, Tianjin, Liaoning and other provinces and cities, among which there are a large number of animal vaccine listed companies in Shanghai, including Shenlian Biotechnology and Haili Biologics.

Industry development prospects and trend forecasts

1. Development trend: pet vaccines and non-mandatory vaccines have great development potential

In recent years, China has continuously strengthened the prevention and control of rabies, actively increased the immunization density of dogs, and promoted the elimination of dog-to-human rabies. Animal rabies vaccine needs to be vaccinated every year, and with the rapid growth of the number of pets in recent years (the number of pet dogs and cats in China's cities and towns will reach 121.55 million in 2023), there is room for continuous growth of animal rabies vaccine. In addition, the cooperation of pet hospitals + pet pharmaceutical companies will accelerate the development of the domestic pet drug market, including the development of the pet vaccine market.

In addition, the new animal epidemic prevention law will help give full play to the subjective initiative and participation of business entities in all links of the industrial chain, and help promote the improvement of the penetration rate of market-oriented vaccines, and the leading animal protection enterprises may benefit. In addition, the diversification of non-mandatory vaccine products will also stimulate industry demand and drive the development of the non-mandatory vaccine industry.

2. Development prospects: The scale of the animal vaccine industry is expected to reach $3.8 billion in 2029

In the future, with the advancement of the commercialization process of non-plague vaccines, it will contribute good market momentum to the animal vaccine market, and with the enhancement of residents' awareness of pet welfare, the application penetration of pet vaccines will increase, and the scale of China's animal vaccine industry is expected to reach 3.8 billion US dollars by 2029.

For more research and analysis of this industry, please refer to the "Analysis Report on the Development Prospects and Investment Strategic Planning of China's Animal Vaccine Industry" by the Prospective Industry Research Institute.

At the same time, the Prospective Industry Research Institute also provides solutions such as industrial new track research, investment feasibility study, industrial planning, park planning, industrial investment, industrial map, industrial big data, smart investment promotion system, industry status certification, IPO consulting/fundraising feasibility study, and specialized and special new small giant declaration. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.

More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers. More enterprise data, enterprise information, and enterprise development are all in the [Qichamao APP], the most cost-effective and most comprehensive enterprise query platform.